|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 239.60 USD | -2.32% |
|
-1.93% | +15.37% |
| 01:33am | US FDA approves Johnson & Johnson's blood cancer drug after speedy review | RE |
| 01:29am | Johnson & Johnson's Janssen Biotech Unit Secures US FDA Approval for Multiple Myeloma Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | Other Pharmaceuticals | -2.67% | -1.93% | +15.37% | +44.60% | +52.96% | 59TCr |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- JNJ Stock
- Charts Johnson & Johnson
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition